High-Performance Liquid Chromatographic Method for Determination of Phenytoin in Rabbits Receiving Sildenafil

被引:0
|
作者
Khedr, Alaa [1 ]
Moustafa, Mohamed [1 ]
Abdel-Naim, Ashraf B. [1 ]
Alahdal, Abdulrahman [1 ]
Mosli, Hisham [1 ]
机构
[1] King Abdulaziz Univ, Fac Pharm, Jeddah, Saudi Arabia
来源
ANALYTICAL CHEMISTRY INSIGHTS | 2008年 / 3卷
关键词
phenytoin; sildenafil; rabbit plasma; chromatography;
D O I
暂无
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A validated high-performance liquid chromatographic (HPLC) method for determination of phenytoin (PHN), para-hydroxy metabolite of phenytoin (POH) and sildenafi l (SIL) in rabbit plasma is described. The method is based on extraction on Sep-Pak C-18 solid support using ethyl acetate and ether as eluents and monitoring at 220 nm. The extracted samples were analyzed by HPLC using Agilent Zorbax Extended C-18 column (150 mm x 4.6 mm internal diameter) and isocratic elution with a mobile phase consist of 29% acetonitrile and 71% sodium acetate solution (0.02 M, pH 4.6). The method was fully validated for linearity and range, selectivity, precision, stability, recovery, and robustness. The linearity of the method was in the range of 0.15 to 39 mu g/ml for PHN and 0.15 to 33 mu g/ml for both POH and SIL. Limits of detection (LOD) of PHN, POH, and SIL were 0.15 +/- 0.01, 0.15 +/- 0.01, and 0.15 +/- 0.01 mu g/ml, respectively. The % recovery of PHN, POH, and SIL from rabbit plasma were, 101.88 +/- 0.12, 99.16 +/- 0.25, and 99.49 +/- 0.33, respectively. The method was applied on plasma collected from rabbits at different time intervals after receiving 30 mg/kg PHN-Na with (and without) 8 mg/kg SIL citrate.
引用
收藏
页码:61 / 67
页数:7
相关论文
共 50 条
  • [21] High-performance liquid chromatographic method for the determination of dasatinib in rabbit plasma using fluorescence detection and its application to a pharmacokinetic study
    Kassem, Mohammed G.
    Ezzeldin, Essam
    Korashy, Hesham M.
    Mostafa, Gamal A. E.
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2013, 939 : 73 - 79
  • [22] Chromatographic retention of adamantane derivatives in high-performance liquid chromatography
    N. Yu. Shumskaya
    S. V. Kurbatova
    O. G. Larionov
    Russian Journal of Physical Chemistry, 2006, 80 : 435 - 439
  • [23] Chromatographic retention of adamantane derivatives in high-performance liquid chromatography
    Shumskaya, N. Yu.
    Kurbatova, S. V.
    Larionov, O. G.
    RUSSIAN JOURNAL OF PHYSICAL CHEMISTRY, 2006, 80 (03): : 435 - 439
  • [25] Development of chiral stationary phases for high-performance liquid chromatographic separation
    Tang, Mengling
    Zhang, Jing
    Zhuang, Shulin
    Liu, Weiping
    TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2012, 39 : 180 - 194
  • [26] A High-Performance Liquid Chromatography:Chemiluminescence Method for Potential Determination of Vardenafil in Dietary Supplement
    Di, Youjun
    Zhao, Min
    Nie, Yingchun
    Wang, Fei
    Lv, Jiagen
    JOURNAL OF AUTOMATED METHODS & MANAGEMENT IN CHEMISTRY, 2011,
  • [27] Determination of Carbonyl Compounds by High-Performance Liquid Chromatography
    K. A. Dychko
    V. V. Khasanov
    G. L. Ryzhova
    T. T. Kuryaeva
    Russian Journal of Applied Chemistry, 2001, 74 : 702 - 703
  • [28] Determination of carbonyl compounds by high-performance liquid chromatography
    Dychko, KA
    Khasanov, VV
    Ryzhova, GL
    Kuryaeva, TT
    RUSSIAN JOURNAL OF APPLIED CHEMISTRY, 2001, 74 (04) : 702 - 703
  • [29] High-performance liquid chromatographic determination of the oxidation products of 2-isopropylnaphthalene and 2,6-diisopropylnaphthalene
    J. Zawadiak
    B. Orlińska
    Z. Stec
    Fresenius' Journal of Analytical Chemistry, 2000, 367 : 502 - 506
  • [30] SIMULTANEOUS DETERMINATION OF FELBAMATE, PRIMIDONE, PHENOBARBITAL, CARBAMAZEPINE, 2 CARBAMAZEPINE METABOLITES, PHENYTOIN, AND ONE PHENYTOIN METABOLITE IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    ROMANYSHYN, LA
    WICHMANN, JK
    KUCHARCZYK, N
    SHUMAKER, RC
    WARD, D
    SOFIA, RD
    THERAPEUTIC DRUG MONITORING, 1994, 16 (01) : 90 - 99